Interleukin-17 and kidney allograft outcome

Area of Science:

• Nephrology
• Immunology
• Transplant Science

Background:

• Acute rejection episodes (ARE) are significant complications following kidney transplantation.
• The proinflammatory cytokine interleukin-17 (IL-17) is implicated in various human and mouse conditions.
• Limited research has evaluated IL-17 levels in kidney transplant recipients.

Purpose of the Study:

• To investigate the correlation between quantitative IL-17 levels and clinical outcomes in kidney transplant patients.
• To assess the role of IL-17 in the pathophysiology of acute kidney rejection.

Main Methods:

• A cross-sectional study involving 19 kidney transplant recipients with isolated kidney grafts.
• IL-17 levels were measured using an enzyme-linked immunosorbent assay (ELISA) in patients with and without signs of rejection, and in healthy controls.
• Clinical data including demographic information, cold ischemia time, HLA mismatches, and immunosuppressive treatment were analyzed.

Main Results:

• IL-17 levels were significantly higher in patients experiencing acute rejection (125.7 +/- 27.06 pg/mL) compared to those without rejection (30 +/- 13.32 pg/mL) (P < .05).
• Healthy controls exhibited no detectable IL-17 levels.
• ARE signs were present in 47% of the studied patients.

Conclusions:

• Interleukin-17 (IL-17) is implicated in the pathophysiology of acute kidney rejection.
• Quantitative IL-17 levels may serve as a biomarker for diagnosing acute kidney transplant rejection.